[go: up one dir, main page]

BR112015026512A2 - composto acetamida heterocíclico - Google Patents

composto acetamida heterocíclico

Info

Publication number
BR112015026512A2
BR112015026512A2 BR112015026512A BR112015026512A BR112015026512A2 BR 112015026512 A2 BR112015026512 A2 BR 112015026512A2 BR 112015026512 A BR112015026512 A BR 112015026512A BR 112015026512 A BR112015026512 A BR 112015026512A BR 112015026512 A2 BR112015026512 A2 BR 112015026512A2
Authority
BR
Brazil
Prior art keywords
disease
compound
positive allosteric
dopamine
receptor
Prior art date
Application number
BR112015026512A
Other languages
English (en)
Other versions
BR112015026512B1 (pt
Inventor
Moritomo Hiroyuki
Ohmiya Makoto
Shiraki Ryota
Kawakami Shimpei
Tobe Takahiko
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of BR112015026512A2 publication Critical patent/BR112015026512A2/pt
Publication of BR112015026512B1 publication Critical patent/BR112015026512B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)

Abstract

resumo “composto acetamida heterocíclico” [problema]um composto que é útil como um modulador alostérico positivo do receptor d1 de dopamina (d1 pam) é fornecido. [meios para a solução]os presentes inventores estudaram um composto que tem uma atividade moduladora alostérica positiva do receptor d1 de dopamina e é útil como um ingrediente ativo de uma composição farmacêutica para prevenir e/ou tratar disfunção cognitiva, sintomas negativos de esquizofrenia, doença de parkinson, doença de alzheimer, doença de huntington, toxicodependências, ou semelhantes e, assim, descobriram que um composto acetamida heterocíclico tem uma atividade moduladora alostérica positiva do receptor d1 de dopamina, desse modo completando a presente invenção. o composto acetamida heterocíclico da presente invenção tem uma atividade moduladora alostérica positiva do receptor d1 de dopamina e pode ser usado como um agente para prevenir e/ou tratar disfunção cognitiva, sintomas negativos de esquizofrenia, doença de parkinson, doença de alzheimer, doença de huntington, toxicodependências, ou semelhantes.
BR112015026512-0A 2013-04-18 2014-04-18 Composto de acetamida heterocíclico ou um sal deste, composição farmacêutica compreendendo dito composto e uso do mesmo BR112015026512B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013087151 2013-04-18
JP2013-087151 2013-04-18
PCT/JP2014/061007 WO2014171528A1 (ja) 2013-04-18 2014-04-18 ヘテロ環酢酸アミド化合物

Publications (2)

Publication Number Publication Date
BR112015026512A2 true BR112015026512A2 (pt) 2017-07-25
BR112015026512B1 BR112015026512B1 (pt) 2023-03-14

Family

ID=51729480

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015026512-0A BR112015026512B1 (pt) 2013-04-18 2014-04-18 Composto de acetamida heterocíclico ou um sal deste, composição farmacêutica compreendendo dito composto e uso do mesmo

Country Status (33)

Country Link
US (2) US8937087B2 (pt)
EP (1) EP2987793B1 (pt)
JP (1) JP6252582B2 (pt)
KR (1) KR102193247B1 (pt)
CN (1) CN105121435B (pt)
AR (1) AR095883A1 (pt)
AU (1) AU2014254768B2 (pt)
BR (1) BR112015026512B1 (pt)
CA (1) CA2909783C (pt)
CY (1) CY1119754T1 (pt)
DK (1) DK2987793T3 (pt)
EA (1) EA028968B1 (pt)
ES (1) ES2651866T3 (pt)
HR (1) HRP20171786T1 (pt)
HU (1) HUE036054T2 (pt)
IL (1) IL241962B (pt)
LT (1) LT2987793T (pt)
ME (1) ME02891B (pt)
MX (1) MX2015014646A (pt)
MY (1) MY175971A (pt)
NO (1) NO2987793T3 (pt)
NZ (1) NZ713118A (pt)
PH (1) PH12015502341B1 (pt)
PL (1) PL2987793T3 (pt)
PT (1) PT2987793T (pt)
RS (1) RS56865B1 (pt)
SA (1) SA515370015B1 (pt)
SG (1) SG11201508448RA (pt)
SI (1) SI2987793T1 (pt)
SM (1) SMT201700594T1 (pt)
TW (1) TWI625329B (pt)
UA (1) UA116243C2 (pt)
WO (1) WO2014171528A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR105025A1 (es) * 2015-06-19 2017-08-30 Astellas Pharma Inc Compuesto de imidazodiazepina
TWI725408B (zh) 2018-04-20 2021-04-21 美商美國禮來大藥廠 多巴胺d1受體正向異位調節劑
WO2020053282A1 (de) 2018-09-13 2020-03-19 Bayer Aktiengesellschaft Heterocyclen-derivate als schädlingsbekämpfungsmittel
CN110590576A (zh) * 2019-08-15 2019-12-20 安徽金禾实业股份有限公司 一种4-多氟代甲氧基邻苯二胺的制备方法
CN114380709B (zh) * 2021-12-31 2023-07-21 西北农林科技大学 4-氯-2-酰氨基酚的合成方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2674524B1 (fr) * 1991-03-25 1993-05-21 Adir Nouveaux amides alkyl heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US6380210B1 (en) 1999-04-02 2002-04-30 Neurogen Corporation Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
BR0009539A (pt) 1999-04-02 2006-06-06 Neurogen Corp composto, composição farmacêutica, método para tratamento ou prevenção de uma doença ou distúrbio associado com agonismo patogênico, agonismo inverso ou antagonismo do receptor gaba a, uso de um composto, método para localizar receptores gaba a em uma amostra de tecido, método para alterar a atividade transdutora de sinal de receptores gaba a, método para o tratamento ou prevenção de distúrbios psicológicos associados com modulação do complexo receptor gaba a, e, processo para a preparação de um composto
US6627624B1 (en) 1999-04-02 2003-09-30 Neurogen Corporation Aryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
AUPQ309399A0 (en) 1999-09-28 1999-10-21 Fujisawa Pharmaceutical Co., Ltd. Benzothiazoline derivatives
ES2349118T3 (es) 2001-09-14 2010-12-28 High Point Pharmaceuticals, Llc Nuevos derivados de aminoazetidina, pirrolidina y piperidina.
US7361671B2 (en) 2001-11-15 2008-04-22 The Institute For Pharmaceutical Discovery, Inc. Substituted heteroarylalkanoic acids
WO2003077847A2 (en) 2002-03-12 2003-09-25 Merck & Co., Inc. Substituted amides
WO2004082605A2 (en) 2003-03-14 2004-09-30 Merck & Co. Inc. Bicyclic anilide spirohydantoin cgrp receptor antagonists
CA2554774A1 (en) * 2004-02-23 2005-09-01 Dainippon Sumitomo Pharma Co., Ltd. Novel heterocyclic compound
DE602005016244D1 (de) 2004-05-27 2009-10-08 Ucb Pharma Sa Benzoxazolonderivate, verfahren zu deren herstellung und deren anwendungen
US7790726B2 (en) 2005-08-16 2010-09-07 Chemocentryx, Inc. Monocyclic and bicyclic compounds and methods of use
WO2007044885A2 (en) 2005-10-11 2007-04-19 Chemocentryx, Inc. Piperidine derivatives and methods of use
CL2007002097A1 (es) 2006-07-20 2008-01-18 Smithkline Beecham Corp Compuestos derivados de pirrolidina o morfolina antagonistas de urotensina ii; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar insuficiencia cardiaca congestiva, insuficiencia cardiaca isquemica, angina, isquemia del miocardio, vejiga hiperactiva, asma y/o copd, entre otras.
US7786157B2 (en) 2007-03-16 2010-08-31 Chemocentryx, Inc. OXO-imidazolidines as modulators of chemokine receptors
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
GB0713686D0 (en) * 2007-07-13 2007-08-22 Addex Pharmaceuticals Sa New compounds 2

Also Published As

Publication number Publication date
US20140315963A1 (en) 2014-10-23
DK2987793T3 (en) 2017-12-18
MX2015014646A (es) 2016-03-01
KR20150143468A (ko) 2015-12-23
RS56865B1 (sr) 2018-04-30
LT2987793T (lt) 2018-01-10
PL2987793T3 (pl) 2018-05-30
AU2014254768B2 (en) 2017-10-05
CN105121435B (zh) 2017-09-29
CN105121435A (zh) 2015-12-02
SG11201508448RA (en) 2015-11-27
TW201518298A (zh) 2015-05-16
EP2987793A4 (en) 2016-09-07
AU2014254768A1 (en) 2015-11-05
JPWO2014171528A1 (ja) 2017-02-23
EP2987793B1 (en) 2017-10-25
ME02891B (me) 2018-04-20
HRP20171786T1 (hr) 2018-02-23
TWI625329B (zh) 2018-06-01
UA116243C2 (uk) 2018-02-26
US9708307B2 (en) 2017-07-18
NZ713118A (en) 2019-03-29
JP6252582B2 (ja) 2017-12-27
SMT201700594T1 (it) 2018-01-11
CA2909783C (en) 2021-02-02
NO2987793T3 (pt) 2018-03-24
BR112015026512B1 (pt) 2023-03-14
SA515370015B1 (ar) 2017-11-27
EA201591988A1 (ru) 2016-02-29
WO2014171528A1 (ja) 2014-10-23
HK1214248A1 (zh) 2016-07-22
CY1119754T1 (el) 2018-06-27
EP2987793A1 (en) 2016-02-24
SI2987793T1 (en) 2018-02-28
US8937087B2 (en) 2015-01-20
MY175971A (en) 2020-07-19
CA2909783A1 (en) 2014-10-23
PH12015502341B1 (en) 2018-10-24
ES2651866T3 (es) 2018-01-30
PT2987793T (pt) 2017-12-19
KR102193247B1 (ko) 2020-12-22
AR095883A1 (es) 2015-11-18
US20150045402A1 (en) 2015-02-12
IL241962B (en) 2019-03-31
PH12015502341A1 (en) 2016-02-22
HUE036054T2 (hu) 2018-06-28
EA028968B1 (ru) 2018-01-31

Similar Documents

Publication Publication Date Title
CL2016002812A1 (es) Uso de ácido 3-2,3,5,6-tetrafluoro-3-trifluorometoxi-bifenil-4-ilcarbamoil-tiofeno-2-carboxílico para preparar un medicamento útil para tratar una enfermedad ocular que es uveítis, ojo seco o causada por un adenovirus composición formulación.
PE20151655A1 (es) Aglomerados respirables de particulas de vehiculo porosas y farmaco micronizado
BR112015026512A2 (pt) composto acetamida heterocíclico
BR112016024472A2 (pt) composto, medicamento, métodos para modulação alostérica positiva e para profilaxia ou tratamento de doenças, e, uso de um composto
BR112015023658A2 (pt) formulação de vitamina d de liberação modificada, estabilizada e método de administração desta
BR112015031903A2 (pt) composto, sal farmaceuticamente aceitável do composto, composição farmacêutica e utilização de um composto
BR112014026493A2 (pt) derivados de imidazotiadiazol como inibidores do receptor ativado por protease 4 (par4) para tratar a agregação de plaqueta
MX2019003467A (es) Formulaciones y metodos para la administracion vaginal de antiprogestinas.
BR112017006113A8 (pt) usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits.
BR112017014740A2 (pt) composto espiro tricíclico
BR112015020963A2 (pt) derivado de 2-acilaminotiazola ou sal do mesmo
BR112016006444A2 (pt) derivado de triazolopirazina e uso do mesmo
BR112016008654B8 (pt) Compostos bicíclicos contendo enxofre, composição farmacêutica compreendendo ditos compostos e uso terapêutico dos mesmos
BR112012015433A2 (pt) composição farmacêutica substancialmente anidra para aplicação cutânea
BR112014016472A8 (pt) formulação farmacêutica estável para administração oral que compreende levocetirizina ou um sal farmaceuticamente aceitável da mesma e montelukast ou um sal farmaceuticamente aceitável do mesmo
BR112021022378A2 (pt) Derivado de tetraidroisoquinolina substituído como um modulador alostérico d1 positivo
CL2011002650A1 (es) Composicion que comprende n-(4-(2-furil)-5-(tetrahidropiran-4-ilcarbonil)tiazol-2-il)-2-metilpiridin-5-carboxamida y l-dopa; uso del compuesto para el tratamiento de un trastorno del movimiento secundario de la terapia con l-dopa; uso del compuesto y l-dopa y/o para el tratamiento y/o profilaxis de la enfermedad de parkinson.
BR112017006690A2 (pt) composto derivado de alfa-aminoamida e composição farmacêutica contendo o mesmo
CL2015002817A1 (es) Formulación del l-5-metiltetrahidrofolato de calcio amorfo (l-5-mthf-ca).
BR112015023694A2 (pt) entrega craniana de fármacos
EA201890120A1 (ru) Многофазные композиции
BR112017015613A2 (pt) gel intestinal de levodopa e carbidopa e métodos de utilização
BR112017015597A2 (pt) moduladores dos receptores da adenosina a3
CO2018000431A2 (es) Compuesto de imidazodiazepina
MX2022014577A (es) Gel intestinal de levodopa y carbidopa y metodos de uso.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/04/2014, OBSERVADAS AS CONDICOES LEGAIS

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 11A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2823 DE 11-02-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.